EQ logo

Equillium (EQ) Company Overview

Profile

Full Name:

Equillium, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

October 12, 2018

Indexes:

Not included

Website:

http://www.equilliumbio.com

Description:

Equillium is a biotechnology company focused on developing innovative therapies for autoimmune and inflammatory diseases. They aim to improve patient outcomes by targeting specific immune pathways, using advanced science to create effective treatments for conditions like lupus and multiple sclerosis.

Key Details

Price

$0.84

Market Cap

$29.63 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$36.08 M(+128.97% YoY)

Annual EPS

-$0.38(+79.46% YoY)

PE Ratio

-

Annual ROE

-48.92%

Annual Debt To Equity

0.00

Beta

1.77

Events Calendar

Earnings

Next earnings date:

Mar 25, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

Mar 25, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Nov 1, 24 Jones Trading
Hold
Aug 19, 24 HC Wainwright & Co.
Buy
Jun 5, 24 HC Wainwright & Co.
Buy
May 17, 24 HC Wainwright & Co.
Buy
Apr 2, 24 HC Wainwright & Co.
Buy
Dec 26, 23 HC Wainwright & Co.
Buy
Nov 13, 23 HC Wainwright & Co.
Buy
Aug 14, 23 HC Wainwright & Co.
Buy
Aug 14, 23 Cantor Fitzgerald
Overweight
May 15, 23 HC Wainwright & Co.
Buy

Screeners with EQ included

Growing Shares Outstanding
Stocks cheaper than 1 dollar
US stocks
Stocks with high beta
Biggest stock losers today
Stocks below SMA 200
Most recommended stocks
Best performing stocks last 3 months
Stocks above SMA 50
Stocks below analysts price target

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$0.84
EQ price is $0.84

Price All-time High

$26.50
EQ price is currently -96.84% below its historical high of $26.50

Price Analysts Target

$4.00
EQ price is currently -79.09% lower than the consensus analysts' forecast

Price Most Recent Change

-9.07%
EQ price was down -9.07% on Feb 7, 2025

Price YTD Change

+11.77%
EQ price is up +11.77% since January 1st

Price 3-Year Change

-79.09%
EQ price is down -79.09% over the past 3 years

Market cap

Market Cap

$29.63 M
EQ market capitalization is $29.63 million

Market Cap 3-Year Change

-74.85%
EQ market capitalization is down -74.85% over the past 3 years

Market Cap All-time High

$469.68 M
EQ market capitalization is currently -93.69% below its historical high of $469.68 million

Market Cap Sector Rank

29.58%
EQ market capitalization is higher than 29.58% of companies in Healthcare sector

Technical

Beta

1.77
EQ beta is 1.77

200-day SMA

$0.92
EQ price is currently -8.66% below its 200-day simple moving average

14-day RSI

63.91
EQ 14-day relative strength index is 63.91

30-day Relative Volume

0.90
EQ 30-day relative volume is 0.90

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$36.08 M
EQ annual revenue is $36.08 million

Annual Revenue Analysts Estimate

$31.85 M
EQ annual revenue is currently +13.29% higher than the consensus analysts' forecast

Annual Revenue 1-Year Change

+128.97%
EQ annual revenue is up +128.97% year-on-year

Annual Revenue Sector Rank

44.04%
EQ annual revenue is higher than 44.04% of companies in Healthcare sector

Profit

Annual Gross Profit

-
EQ annual gross profit value is unknown

Annual Gross Margin

-
EQ annual gross profit margin value is unknown

Annual Operating Profit

-$14.52 M
EQ annual operating income is -$14.52 million

Annual Operating Margin

-40.25%
EQ annual operating profit margin is -40.25%

Annual Net Income

-$13.34 M
EQ annual net profit is -$13.34 million

Annual Net Margin

-36.96%
EQ annual net profit margin is -36.96%

EPS

Annual EPS

-$0.38
EQ annual earnings per share is -$0.38

Annual EPS Analysts Estimate

-$0.52
EQ annual earnings per share is currently -26.92% lower than the consensus analysts' forecast

Annual EPS 1-Year Change

+79.46%
EQ annual earnings per share is up +79.46% year-on-year

Annual EPS Sector Rank

74.21%
EQ annual earnings per share is higher than 74.21% of companies in Healthcare sector

ROA & ROE

Annual ROA

-20.68%
EQ annual return on assets is -20.68%

Annual ROE

-48.92%
EQ annual return on equity is -48.92%

EBIT & EBITDA

Annual EBIT

-$12.26 M
EQ annual earnings before interest & taxes is -$12.26 million

Annual EBITDA

-$12.14 M
EQ annual EBITDA is -$12.14 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
EQ price to earnings ratio value is unknown

PE Ratio Sector Rank

-
EQ price to earnings ratio is unknown

PB Ratio

PB Ratio

1.28
EQ price to book ratio is 1.28

PB Ratio Sector Rank

46.64%
EQ price to book ratio is higher than 46.64% of companies in Healthcare sector

PS Ratio

PS Ratio

0.65
EQ price to sales ratio is 0.65

PS Ratio Sector Rank

17.44%
EQ price to sales ratio is higher than 17.44% of companies in Healthcare sector

Enterprise value

Enterprise Value

$14.68 M
EQ enterprise value is $14.68 million

Enterprise Value Sector Rank

25.51%
EQ enterprise value is higher than 25.51% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-3.29
EQ EV/EBITDA is -3.29

EV/EBITDA Sector Rank

30.64%
EQ EV/EBITDA is higher than 30.64% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

1.79
EQ annual current ratio is 1.79

Annual Quick Ratio

-
EQ annual quick ratio value is unknown

Leverage

Annual Debt To Equity

0.00
EQ annual debt to equity ratio is 0.00

Annual Interest Coverage Ratio

-24.98
EQ annual interest coverage ratio is -24.98

Risk & Stability

Piotroski F-Score

-
EQ piotroski f-score value is unknown

Altman Z-Score

-4.08
EQ altman z-score is -4.08

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$50.53 M
EQ annual total assets is $50.53 million

Annual Non Current Assets

$1.18 M
EQ annual long term assets is $1.18 million

Annual Current Assets

$49.35 M
EQ annual total current assets is $49.35 million

Annual Cash & Cash Equivalents

$23.22 M
EQ annual cash & cash equivalents is $23.22 million

Equity

Annual Book Value

$22.57 M
EQ annual book value is $22.57 million

Annual Working Capital

$21.78 M
EQ annual working capital is $21.78 million

Liabilities

Annual Total Liabilities

$27.96 M
EQ annual total liabilities is $27.96 million

Annual Total Long Term Liabilities

$384.00 K
EQ annual total long term liabilities is $384.00 thousand

Annual Current Liabilities

$27.57 M
EQ annual total current liabilities is $27.57 million

Annual Accounts Payable

$4.71 M
EQ annual accounts payable is $4.71 million

Debt

Annual Total Debt

$824.00 K
EQ annual total debt is $824.00 thousand

Annual Total Debt 1-Year Change

-91.91%
EQ annual total debt is down -91.91% year-on-year

Annual Long Term Debt

$384.00 K
EQ annual long term debt is $384.00 thousand

Annual Short Term Debt

$440.00 K
EQ annual short term debt is $440.00 thousand

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$50.61 M
EQ annual total expenses is $50.61 million

Annual Operating Expenses

$50.61 M
EQ annual total operating expenses is $50.61 million

Annual Cost Of Goods Sold

-
EQ annual cost of goods sold value is unknown

Annual SGA

$13.57 M
EQ annual SGA is $13.57 million

Annual D&A

$126.00 K
EQ annual depreciation & amortization is $126.00 thousand

Annual Interest Expense

$491.00 K
EQ annual interest expense is $491.00 thousand

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$21.78 M
EQ annual cash flow from operations is -$21.78 million

Annual CFO 1-Year Change

-149.43%
EQ annual cash flow from operations is down -149.43% year-on-year

Annual CFI

-$4.76 M
EQ annual cash flow from investing activities is -$4.76 million

Annual CFI 1-Year Change

-125.49%
EQ annual cash flow from investing activities is down -125.49% year-on-year

Annual CFF

-$9.23 M
EQ annual cash flow from financing activities is -$9.23 million

Annual CFF 1-Year Change

-659.51%
EQ annual cash flow from financing activities is down -659.51% year-on-year

Free CashFlow

Annual FCF

-$21.83 M
EQ annual free cash flow is -$21.83 million

Annual FCF 1-Year Change

-142.27%
EQ annual free cash flow is down -142.27% year-on-year

CAPEX

Annual CAPEX

$50.00 K
EQ annual capital expenditures is $50.00 thousand

Annual CAPEX 1-Year Change

-82.08%
EQ annual capital expenditures is down -82.08% year-on-year

Institutional Ownership

Similar stocks

Scienture Holdings (SCNX)
JUNS logo
Jupiter Neurosciences (JUNS)
XLO logo
Xilio Therapeutics (XLO)
INTS logo
Intensity Therapeutics (INTS)
ONMD logo
OneMedNet (ONMD)
NSYS logo
Nortech Systems Incorporated (NSYS)
Cadrenal Therapeutics (CVKD)
MRNS logo
Marinus Pharmaceuticals (MRNS)
WORK Medical Technology Group LTD (WOK)
Equillium, Inc. (EQ) Beats Q2 Earnings and Revenue Estimates
Equillium, Inc. (EQ) Beats Q2 Earnings and Revenue Estimates
Equillium, Inc. (EQ) Beats Q2 Earnings and Revenue Estimates
EQ
zacks.comAugust 8, 2024

Equillium, Inc. (EQ) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.15 per share. This compares to loss of $0.10 per share a year ago.

Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance
Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance
Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance
EQ
businesswire.comJuly 18, 2024

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced second quarter 2024 estimated ending cash, cash equivalents and short-term investments of approximately $33.3 million, representing an increase of approximately $1.0 million from the end of the first quarter of 2024. The increase is primarily the result of receiving a tax credit of.

Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates
Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates
Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates
EQ
Zacks Investment ResearchMarch 25, 2024

Equillium, Inc. (EQ) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to earnings of $0.08 per share a year ago.

5 Top-Ranked Stocks That Have More Than Doubled Year to Date
5 Top-Ranked Stocks That Have More Than Doubled Year to Date
5 Top-Ranked Stocks That Have More Than Doubled Year to Date
EQ
Zacks Investment ResearchFebruary 23, 2024

Amid the broad-market rally, shares of Equillium (EQ), Phunware (PHUN), Super Micro Computer (SMCI), Vaxart (VXRT) and Dianthus Therapeutics (DNTH) have more than doubled this year.

Equillium, Inc. (EQ) Reports Q2 Loss, Tops Revenue Estimates
Equillium, Inc. (EQ) Reports Q2 Loss, Tops Revenue Estimates
Equillium, Inc. (EQ) Reports Q2 Loss, Tops Revenue Estimates
EQ
Zacks Investment ResearchAugust 9, 2023

Equillium, Inc. (EQ) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.41 per share a year ago.

FAQ

  • What is the ticker symbol for Equillium?
  • Does Equillium pay dividends?
  • What sector is Equillium in?
  • What industry is Equillium in?
  • What country is Equillium based in?
  • When did Equillium go public?
  • Is Equillium in the S&P 500?
  • Is Equillium in the NASDAQ 100?
  • Is Equillium in the Dow Jones?
  • When was Equillium's last earnings report?
  • When does Equillium report earnings?
  • Should I buy Equillium stock now?

What is the ticker symbol for Equillium?

The ticker symbol for Equillium is NASDAQ:EQ

Does Equillium pay dividends?

No, Equillium does not pay dividends

What sector is Equillium in?

Equillium is in the Healthcare sector

What industry is Equillium in?

Equillium is in the Biotechnology industry

What country is Equillium based in?

Equillium is headquartered in United States

When did Equillium go public?

Equillium's initial public offering (IPO) was on October 12, 2018

Is Equillium in the S&P 500?

No, Equillium is not included in the S&P 500 index

Is Equillium in the NASDAQ 100?

No, Equillium is not included in the NASDAQ 100 index

Is Equillium in the Dow Jones?

No, Equillium is not included in the Dow Jones index

When was Equillium's last earnings report?

Equillium's most recent earnings report was on Nov 13, 2024

When does Equillium report earnings?

The next expected earnings date for Equillium is Mar 25, 2025

Should I buy Equillium stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions